Potential HER2-positive early breast cancer treatment pathway
Neoadjuvant therapy offers a number of benefits for patients with eBC and is an important treatment option for consideration by a multidisciplinary team.
PHESGO is a new combined fixed-dose subcutaneous (SC) formulation of pertuzumab and trastuzumab that requires just 20–38 minutes for administration and monitoring1
View the effect that PERJETA‑trastuzumab plus chemotherapy has on outcomes in patients with eBC and mBC
View the effect that Kadcyla has on outcomes in early and metastatic patients
*In the adjuvant setting, PHESGO should be administered for a total of one year (up to 18 cycles or until disease recurrence, or unmanageable toxicity, whichever occurs first), as part of a complete regimen for early breast cancer and regardless of the timing of surgery. Treatment should include standard anthracycline- and/or taxane-based chemotherapy.
†For adjuvant PHESGO treatment to be commissioned by NHS England, patients must be node-positive at diagnosis or node-negative at diagnosis and upstaged following surgery.
pCR, pathological complete response; SC, subcutaneous; SLNB, sentinel lymph node biopsy.
- PHESGO Summary of Product Characteristics.
- Senkus E et al. Ann Oncol. 2015;26 Suppl 5:v8–30.
- Kadcyla Summary of Product Characteristics.
- National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632). June 2020.
- Herceptin subcutaneous Summary of Product Characteristics.
- National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management (NG101). July 2018.
- Scottish Medicines Consortium. SMC928/13. January 2014.
Date of preparation: July 2021